As anti-oxidative NADPH level is critically important for chemotherapeutic resistance (Kim et al, 2017), knockdown of ACC2 conferred therapeutic resistance of breast cancer cells against paclitaxel (Fig S4F). This evidence concerns the gene ACACB and breast cancer.